Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang

Group 1 - Sanofi is considered a cheap stock to buy, with Jefferies reiterating its 'Buy' rating and maintaining a price target of €100 despite concerns regarding the FDA's Complete Response Letter for tolebrutinib [1] - The European Commission approved Sanofi's Wayrilz (rilzabrutinib) treatment for immune thrombocytopenia (ITP), based on the successful LUNA 3 phase 3 study that met both primary and secondary endpoints [2] - In the LUNA 3 study, Wayrilz patients showed a faster time to first platelet response at 36 days compared to the placebo group, which did not meet this endpoint, and maintained a platelet response for an additional 6.3 weeks [3] Group 2 - Sanofi, founded in 1994, is a French pharmaceutical company that provides medicines and vaccines for various indications, including immunology, inflammation, and oncology [3]